- Home
- SNSE vs BLRX Comparison
SNSE vs BLRX Comparison
Compare SNSE & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNSE | BLRX |
|---|---|---|
| Founded | 2005 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.2M | 12.6M |
| IPO Year | 2021 | 2011 |
Fundamental Metrics
Financial Performance| Metric | SNSE | BLRX |
|---|---|---|
| Price | $9.09 | $2.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $72.50 | $19.00 |
| AVG Volume (30 Days) | ★ 55.1K | 15.9K |
| Earning Date | 03-27-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $12,735,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.00 | $2.30 |
| 52 Week High | $18.35 | $7.77 |
Technical Indicators
Market Signals| Indicator | SNSE | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.76 | 45.93 |
| Support Level | $8.72 | $2.85 |
| Resistance Level | $9.44 | $3.20 |
| Average True Range (ATR) | 0.69 | 0.17 |
| MACD | -0.08 | -0.01 |
| Stochastic Oscillator | 34.62 | 22.86 |
Price Performance
Historical ComparisonAbout SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.